Inhibition of replication of fresh HIV type 1 patient isolates by a polypurine tract-specific self-complementary oligodeoxynucleotide by Jendis, J et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 1996
Inhibition of replication of fresh HIV type 1 patient isolates by a polypurine
tract-specific self-complementary oligodeoxynucleotide
Jendis, J; Strack, B; Volkmann, S; Böni, J; Mölling, K
Abstract: A previously described self-complementary oligodeoxynucleotide termed triplex-forming oligodeoxynu-
cleotide (TFO A), 54 bases in length, designed against the polypurine tract of HIV-1 RNA, inhibited viral
replication at a 1 to 3 microM concentration in acutely infected cells, whereas antisense and scrambled
sequence oligodeoxynucleotides were ineffective. Three HIV-1 viral isolates from patients of clinical cat-
egories A1, B, and C3 were transmitted to peripheral blood mononuclear cells and tested for production
of p24 antigen and syncytium formation in the absence and in the presence of either TFO A or a control
oligodeoxynucleotide of randomized sequence. No p24 antigen or syncytia were detected for up to 30
days when TFO A was added to the cells. Viability of the cells was found not to be affected by the drugs
compared to controls within 2 weeks. Analysis of viral DNA synthesis by PCR for the LTR and gag gene
indicated no DNA signal, suggesting that TFO A affects viral replication before formation of a DNA
provirus. Measurements of the stability of TFO A indicate a half-life of about 2 hr. A two-dimensional
computer fold analysis of TFO A suggested a self-complementary hairpin-loop configuration with GC-rich
stems and single-stranded 5’ and 3’ ends. Since intracellular triplex formation may not be an efficient
process, the observed inhibitory effect may be due to a direct inhibition of the RT and RNase H enzyme
activities by the oligodeoxynucleotide. However, a triple-helix effect on the incoming RNA may play a
role as well.
DOI: 10.1089/aid.1996.12.1161
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-2190
Published Version
Originally published at:
Jendis, J; Strack, B; Volkmann, S; Böni, J; Mölling, K (1996). Inhibition of replication of fresh HIV type
1 patient isolates by a polypurine tract-specific self-complementary oligodeoxynucleotide. AIDS Research
and Human Retroviruses, 12(12):1161-1168. DOI: 10.1089/aid.1996.12.1161
AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 12, Number 12, 1996
Mary Ann Liebert, Inc.
Inhibition of Replication of Fresh HIV Type 1 Patient Isolates
by a Polypurine Tract-Specific Self-Complementary
Oligodeoxynucleotide
JÖRG JENDIS,1,2 BETTINA STRACK,1 SILKE VOLKMANN,3,4 JÜRG BÖNI,2 and KARIN MÖLLING1
ABSTRACT
A previously described self-complementary oligodeoxynucleotide termed triplex-forming oligodeoxynucleotide(TFO A), 54 bases in length, designed against the polypurine tract of HIV-1 RNA, inhibited viral replication
at a 1 to 3 fiM concentration in acutely infected cells, whereas antisense and scrambled sequence oligodeoxynu-
cleotides were ineffective. Three HIV-1 viral isolates from patients of clinical categories Al, B, and C3 were
transmitted to peripheral blood mononuclear cells and tested for production of p24 antigen and syncytium
formation in the absence and in the presence of either TFO A or a control oligodeoxynucleotide of random-
ized sequence. No p24 antigen or syncytia were detected for up to 30 days when TFO A was added to the
cells. Viability of the cells was found not to be affected by the drugs compared to controls within 2 weeks.
Analysis of viral DNA synthesis by PCR for the LTR and gag gene indicated no DNA signal, suggesting that
TFO A affects viral replication before formation of a DNA provirus.
Measurements of the stability of TFO A indicate a half-life of about 2 hr. A two-dimensional computer fold
analysis of TFO A suggested a self-complementary hairpin-loop configuration with GC-rich stems and sin-
gle-stranded 5' and 3' ends. Since intracellular triplex formation may not be an efficient process, the observed
inhibitory effect may be due to a direct inhibition of the RT and RNase H enzyme activities by the oligodeoxynu-
cleotide. However, a triple-helix effect on the incoming RNA may play a role as well.
INTRODUCTION pairing with the preformed RNA-DNA hybrid, is capable of
triple-helix formation. The four nucleotides at either terminus
We have described a culture system based on the acute and the (T)4 linker were modified by phosphorothioates. Thisinfection of an HTLV-I-transformed T cell line with the molecule is capable of exerting antiviral activity based on triple-
human immunodeficiency virus type 1 (HIV-1) to evaluate the helix interaction. This is because the heteroduplex forms around
long-term efficacy of antiretroviral treatment based on a triple a purine-rich target.3
helix-forming oligodeoxynucleotide.1 It has been shown that a The polypurine tract serves an important function in retro-
synthetic, 54-base long oligodeoxynucleotide (ODN), termed viral replication since it provides the primer for the second-
triplex-forming oligodeoxynucleotide A (TFO A), could inhibit strand DNA synthesis. After a full-length minus-strand DNA
HIV-1 replication in an acute infection, when virus was added copy has been synthesized the RNase H activity of the reverse
to an uninfected susceptible cell line C81-66/45. This transcriptase (RT) catalyzes the hydrolysis of the viral genomic
oligodeoxynucleotide comprises 25 bases complementary to the RNA in the RNA-DNA hybrid.4 RNA complementary to the
extended polypurine tract (PPT) sequence.2 A linker consisting PPT is resistant to RNase H cleavage and serves as primer for
of four thymidines connects this part of the molecule to a sec- second-strand DNA synthesis by the DNA-directed DNA poly-
ond, 25-base long sequence that, by virtue of Hoogsteen base merase activity of the RT. This step is essential for retroviral
'Institut für Medizinische Virologie, Universität Zürich, CH-8028 Zurich, Switzerland.
2Nationales Zentrum für Retroviren, Universität Zürich, CH-8028 Zurich, Switzerland.
3Max-Planck-Institut für Molekulare Genetik, D-14195 Berlin, Germany.
4Present address: Universität Hamburg, Zentrum für Molekulare Neurobiologie, Institut für Neurale Signalverarbeitung, D-20248 Hamburg,
Germany.
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replication and requires a functional RNase H activity.5 The
PPT is a highly conserved region among retroviruses located
adjacent to the unique region at the 3' end (U3) of the viral
genome in the coding region of the HIV nef gene. A second
PPT is located in the coding region of the integrase gene.6 The
PPT can function as a target for triple-helix formation.
Formation of Watson-Crick base pairs between the 3' half of
TFO A and the RNA would result in an RNA-DNA hybrid that
is a substrate for RNase H activity. Using conditions in which
a triple helix could form, no RNase H cleavage was detected,
indicating the formation of Hoogsteen base pairs between the
RNA and the 5' half of TFO A.1 However, in vitro in the pres-
ence of higher concentrations of TFO A (>1 pM) the RT and
the RNase H activity are directly inhibited, as shown by primer-
extension experiments and RNase H assays using a random hy-
brid substrate. In contrast to these in vitro experiments the
mechanism of TFO A inhibition of retroviral replication in cell
culture has not yet been elucidated. The drug is effective at 1
/xM concentration in the culture medium, a concentration that
is in vitro at the borderline between a triple-helix effect and a
direct enzyme inhibition. Whether a synergy of both effects ex-
ists intracellularly is not known.
The TFO A used here contained phosphorothioate modifi-
cations at the 5' and 3'-terminal ends and at the (T)4 linker to
make it resistant against exonucleases and suitable for its ap-
plication in cell culture. The oligodeoxynucleotide is designed
to bind to an extended 25-mer purine-rich target sequence that
encompasses the contiguous 16-mer PPT, two nonpurine bases,
and an additional seven purines. In base triplets containing a
Watson-Crick GC base pair, guanine was used as a third strand
base, rendering the triple helix much more stable under physi-
ological conditions.1
Here we present further evidence for the antiviral efficacy
of TFO A and present data that this oligodeoxynucleotide can
also inhibit viral replication of primary clinical HIV-1 isolates
obtained from three seropositive individuals and transmitted to
peripheral blood mononuclear cells (PBMCs) in culture.
Furthermore, we show that the TFO A exerts an inhibitory ef-
fect before DNA provirus formation.
MATERIALS AND METHODS
Oligodeoxynucleotides
Oligodeoxynucleotides (ODNs) were synthesized on an
Applied Biosystems (Foster City, CA) 380 B synthesizer using
standard phosphoramidate chemistry and were purified as de-
scribed.1 Phosphorothioated ODNs were purchased from Biotez(Berlin, Germany). The following ODNs were used: phospho-
rothioated TFO A (5' TsTsTsTCTTTTGGGGGGTTTGGTT-
GGGsTsTsTsTCCCTTCCAGTCCCCCCTTTTCTsTsTsT).
consisting of a Watson-Crick-forming sequence of 25 nu-
cleotides directed against the extended PPT (underlined), a triple
helix-forming sequence of 25 nucleotides (italics), connected by
a T linker of 4 nucleotides. The j indicates the thioate modifica-
tions. A scrambled version of TFO A, used as control, was
named TFO SC (5' TsTsTsGGGGGGTTCTTCCTCTTTCCT-
TsTsTsTsTCGCCCGTCCGTTGCGTTGATTTsTsTsT). As a
further specificity control TFO B (5' TsGsTsGTGTGTGTG-
TGTGTGTGTGTGTsTsTsTsTCCCTTCCAGTCCCC-
CCTTTTCTsTsTsT) was used. Furthermore, a thioated 16-mer
PPT antisense ODN designated AS 16 (5' TCCCCCC-
TTTTCTsTsTsT) corresponding to the Watson-Crick base-pair-
ing sequence of the TFO A, and a scrambled derivative of the
latter termed KO 16 (5' TCCTCCTCTTCTTsCsTsT), were
tested for antiretroviral activity. Also, the corresponding 16-
mer ODNs protected by an amino group at their 3' end were
used.
Assay for inhibition of HIV-1 replication in cell
cultures of the T cell line C81-66/45
Phosphorothioate ODNs and ODNs modified by an amino
group replacing the 3'-hydroxyl group were tested for antiviral
activity in a cellular acute infection assay. In this assay the
HTLV-I-transformed T cell line C81-66/45 was used (kindly
provided by R. C. Gallo, NCI, NIH, Laboratory of Tumor Cell
Biology, Bethesda, MD).7 To study the effect of the ODNs in
cell culture, the following the TFOs were used: TFO A, TFO
SC; in addition, thioated 16-mer PPT antisense ODNs desig-
nated AS 16, and scrambled derivatives of these ODNs that
were either phosphorothioate modified (AS 16 S; KO 16 S) or
protected by an amino group at their 3' end (AS 16 A, KO 16
A), were tested for antiretroviral activity. HIV-1 replication was
investigated in experiments as described.1 Briefly, 2 X 105
C81-66/45 cells/well of a 48-well plate were infected with HIV-
1 strain HTLV-IIIB8 containing supernatant that had been
titrated for determination of infectivity. We used a low multi-
plicity of infection (MOI 0.05). Viable cell number increased
to 1 X 106 cells/ml within 4 days of incubation as determined
by trypan blue exclusion. Once a week viable cells were counted
and split down to 1 X 106 cells/ml. HIV-1 infection of C81-
66/45 cells is characterized by the appearance of large syncy-
tia in culture that can be detected by microscope. Two hours
postinfection the cells were washed and treated with the ODNs
at indicated concentrations in culture medium (first spike). After
48 hr the supernatant was removed and fresh medium was added
again containing the ODNs at an identical concentration (sec-
ond spike). After 4 to 5 days medium was replaced by fresh
medium without ODNs for the remainder of the cultivation pe-
riods. Virus production was monitored at the cellular level by
the appearance of syncytia and in the supernatants by p24 anti-
gen-capture assay using the Du Pont HIV-1 p24 core profile
ELISA (Du Pont de Nemours GmbH, Bad Nauheim, Germany).
At the time points indicated, culture supernatant was removed
for p24 antigen analysis and replaced by fresh medium.
Supernatants were tested in serial dilutions and p24 values in-
dicated in Figs. 1-3 were derived from the linear range. In these
experiments the effect of TFO A in comparison to TFO SC, the
pair of PPT antisense ODNs (AS 16 S, AS 16 A), and their
control ODNs (KO 16 S, KO 16A) mentioned above, were an-
alyzed over a time period of 17 days.
Assay for inhibition of replication offresh HIV-1
patient isolates in cultures ofperipheral blood
mononuclear cells of healthy Swiss blood donors
The HIV isolates used for these experiments were obtained
as supernatant virus from cocultures established from the
PBMCs of three HIV-1-seropositive individuals, consisting of
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one asymptomatic (AI) and two symptomatic (B and C3), with
PBMCs obtained from buffy coats of healthy seronegative
Swiss blood donors as recipient cells for the virus. Cocultures
were performed according to a method described by Ho et al.9
Supernatants of the cocultures were saved with each medium
change, stored at 4°C, and later tested for p24 viral antigen.
Nine days postinfection maximum amounts of viral core anti-
gen could be demonstrated in the culture supernatant. These su-
pernatants were then subjected to filtration through a 0.45-/_,m
pore size nitrocellulose filter (Sartorius, Goettingen, Germany)
to remove all cells and cell debris and then added to freshly
prepared PBMCs from another normal seronegative Swiss
blood donor to serve as target cells for HIV-1 replication of the
new viral isolate. PBMCs (1.8 X 106) were cell-free infected
with the virus for 2 hr and split into three parts, with and with-
out TFO A treatment as well as scrambled (TFO SC) control
added at 1 pM concentration in two spikes; see Fig. 3A-C.
Detection of viral DNA in peripheral blood
mononuclear cell cultures by polymerase chain
reaction
Viral DNA in infected PBMCs was detected by a qualitative
polymerase chain reaction (PCR) analysis. Total cellular DNA
was prepared by detergent lysis and proteinase treatment ac-
cording to the method described by Higuchi.10 Amplifications
with the DNA equivalent of 2 X 105 cells per reaction were car-
ried out in duplicate for 35 cycles using primers HIV-L1 and
L3, and H1Y-G1 and G2 for the long terminal repeat (LTR) and
gag regions, respectively.11 The resulting products were identi-
fied by a nonisotopic detection system that is based on solution
hybridization of the amplified DNA with two oligodeoxynu-
cleotide probes that are labeled with biotin and digoxigenin.
After binding of the hybrid molecules to a solid phase, the digox-
igenin tag is detected by an enzyme linked immunosorbent as-
say.12 Oligonucleotide probes used for gag and LTR sequences
were, respectively, HIV-G3-BIO (5' AGTGGATAATC-
CTGGGATTAAATA 3') and HIV-G7-DIG (5' AATAGTAA-
GAATGTATAGCCCT 3'), and HIV-L2-BIO (5' GGTCT-
GAGGGATCTCTAGTTACCAG 3') and HIV-L7-DIG (5'
GCACTCAAGGCAAGCTTTATTGAGGC 3'). This PCR
analysis has the ability to detect a single copy of HIV-1 DNA.
Analysis of triplex-forming oligodeoxynucleotide
stability
TFO A and TFO SC were 5' end-labeled using [7 -32P]ATP
in the presence of T4 polynucleotide kinase. The radioactively
labeled TFOs were added to 1 ml of C81-66/45 cells (2 X 105
cells/ml of RPMI 1640 medium containing 20% heat-inacti-
vated fetal bovine serum) to a final concentration of 1 pM (1 X
108 cpm/pmol). After various times of cell growth 50-pl
aliquots of the cell suspension were taken and the cells were
lysed by addition of 20 pi of lysis buffer (400 inM NaCl, 40
mM Tris-HCl [pH 8.0], 100 mM EDTA, and 2% sodium do-
decyl sulfate [SDS]). For definition of the zero time point, the
50-pl aliquot was taken immediately after the addition of the
TFOs to the cells. After phenol extraction an aliquot of the aque-
ous phase was subjected to electrophoresis using a denaturing
12% polyacrylamide gel containing 7 M urea. The amount of
undegraded TFO was quantitated by means of phosphorimag-
ing. The so-called splayed-arm structure consisting of a branch
point with adjacent single-stranded regions has been shown to
be the substrate of a new type of endonucleolytic activity.13
RESULTS
Inhibitory effect of oligodeoxynucleotides on HTV-1
Infection of T cells
The HIV RNA genome contains two polypurine-rich se-
quences (PPTs). These PPTs constitute potential target sites for
triple-helix formation. Blockage of the biological function of
these sequences could also be accomplished by the use of an-
tisense ODNs directed against the PPT. Syncytium formation
was determined by microscope and graded and p24 production
measured by enzyme-linked immunosorbent assay (ELISA).
We first compared the antiviral effect of TFO A with 16-mer
antisense ODN (AS 16 A and AS 16 S, 1 pM. concentration)
allowing Watson-Crick base pairing at the PPT.
Oligodeoxynucleotides with a randomized sequence were used
as control (KO 16 A and KO 16 S). No inhibitory effect of the
AS is observed when the kinetics of p24 production are com-
pared to those of the cultures that received the control or no
ODN treatment (Fig. 1). In all three cultures p24 productions
without TFO
AS 16 A
KO 16 A
AS 16 S
KO 16 S
TFO A
10'"' 15 20
days post infection
ODN spike
48 hrs post
infection
ODN spike
2 hrs post
infection
FIG. 1. Antiviral effects of phosphorothioate-modified TFO
A in comparison to its corresponding 16-mer antisense ODN(AS 16) and a scrambled derivative ODN (KO 16) that were
either phosphorothioate modified (AS 16 S; KO 16 S) or pro-
tected by an amino group at the 3' end (AS 16 A; KO 16 A).
Cultures consisted of C81 -66/45, an HTLV-I-transformed T cell
line newly infected with HIV-1 type IIIB. After 2 hr of incu-
bation with the virus cells were washed and treated with the
ODNs (1 pM). The second treatment was performed 48 hr later,
including a change of the medium (RPMI 1640 plus 20% heat-
inactivated fetal bovine serum [GIBCO, Life Technologies,
Basel, Switzerland]). As control one culture was tested without
added ODN. Supernatants were collected and viral antigen ex-
pression determined by p24 antigen capture assay. The amount
of p24 (ng) per 1 X 106 cells was plotted as a function of time.
Syncytium formation was determined by microscope and is
graded (-, +/- to + + +).
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started at day 7 postinfection, increased subsequently to peak
levels, and declined gradually thereafter. Slightly better pro-
tection results were obtained with a 16-mer antisense ODN,
protected against degradation by three phosphorothioated de-
oxynucleotides at either end (AS 16 S), and a randomized con-
trol (KO 16 S). Treatment of infected cells with these phos-
phorothioate derivatives prevented syncytium formation for up
to 10 days. Figure 1 shows that development of high levels of
viral replication in the culture treated with AS 16 S occurred 4
days later as compared to cultures that received either AS 16
A or its control. However, the randomized phosphorothioate
control KO 16 S exhibited an even more pronounced delay on
viral replication, indicating nonspecific effects. In contrast to
that, treatment of cells with TFO A led to a complete inhibi-
tion of viral replication as measured by p24 production.
Inhibition ofHTV-1 infection by TFO A is dose
dependent
To elucidate further the antiviral effect of the most potent
inhibitor, TFO A, a variety of different concentrations of the
compound were tested. A dose-response curve for p24 pro-
duction as a measure of HIV-1 IIIB inhibition is shown (Fig.
2). TFO A was added twice as described above. Protection
against HIV-1 cytopathicity is achieved at 1 to 3 pM concen-
trations. Up to 10 days after infection no cytopathic effect is
observed in these cultures at the higher TFO A concentration.
HIV-1 p24 production in the culture supernatant is inhibited by
64% at 1 |U,M concentration in comparison to the culture with-
out TFO treatment. A beginning cytopathic effect in this cul-
ture is noticed only 10 days postinfection. Thus, at 1 pM con-
centration the drug is able to effectively delay virus production
and the onset of the cytopathic effects in acutely infected CD4+
T cells. Higher amounts of p24 antigen production were mea-
sured in the supernatants in cultures containing 0.1 and 0.5 pM
concentrations of TFO A than in untreated cultures 17 days
postviral infection. A complete inhibition is achieved at a 3 pM
concentration of TFO A, which is higher than previously de-
scribed and where a complete inhibitory effect was observed
with 1 ¿iMTFO A.1
We have investigated antiviral activities of antisense and
triplex-forming oligodeoxynucleotides by using acutely in-
fected cells of an established T cell line as assay system. To
exclude the possibility that TFO A can inhibit only a single lab-
oratory propagated viral strain, we also used three patient iso-
lates for elucidation of the biological effects of TFO A.
TFO A inhibits the infection of peripheral blood
mononuclear cells with clinical HTV-1 isolates
We used a two-step procedure to obtain and test the HIV iso-
lates. First, the PBMCs of the seropositive individual (asymp-
tomatic of category Al of HIV infection) were cocultured with
PBMCs prepared from a seronegative blood donor at a 1:1 ra-
tio. Filtered supernatants that contained high amounts of p24
antigen were then transmitted to PBMCs obtained from a sec-
ond seronegative blood donor as target cells for viral replica-
tion. This two-step cell-free virus transmission resembles the
previously described acutely infected C81-66/45 cell system.1
Cells were incubated with the virus for 2 hr. Infected cells were
then washed and TFOs were added with fresh medium. In con-
trast to the previously described experiments using the cell line
C81-66/45 new medium supplemented with TFOs was added
again after 24 hr. TFO A completely blocked viral replication
as measured by p24 production (Fig. 3A). Furthermore, no cy-
topathic effect was detected in this culture. In contrast, p24 pro-
duction was observed in the culture treated with the random se-
quence ODN TFO SC and in the control culture that received
no treatment. The culture treated with TFO SC produced
slightly lower amounts of virus throughout the culture period
125
100 4
grading of
cytopathic effect
day 4 day 10
D- Without TFO ( + ) (+++)
0. 0.1nM TFO A ( + /-) ( + + + )
O---- 0.5pM TFO A (+/-) ( + + + )
A—- 1.0O.M TFO A (-) ( + )
IB--- 3.0nM TFO A (-) (-)
days post infection
ODN spike
48 hrs post
infection
ODN spike
2 hrs post
infection
FIG. 2. Antiviral effects of increasing concentrations of TFO A. TFO A was added twice, at 2 and 48 hr following viral in-
fection, to C81-66/45 T cells at concentrations as indicated. Determination of p24 expression and syncytium formation was per-
formed as described in the caption to Fig. 1.
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FIG. 3. Antiviral effects of TFO A and TFO SC on fresh HIV
patient isolates transmitted to cultures of PBMCs of healthy
seronegative Swiss blood donors. HIV isolates were obtained
as supernatant virus from cocultures established from PBMCs
of an HIV-seropositive individual with PBMCs from seroneg-
ative blood donors as recipient cells for the virus. Cocultures
were incubated for 24 hr in medium containing phytohemag-
glutinin (PHA-P at 2 pg/ml; Sigma, St. Louis, MO) and there-
after transferred to medium containing 5% interleukin 2(Cellular Products, Buffalo, NY). Nine days postinfection 1 ml
of virus-containing supernatant, as measured by p24 antigen
capture assay, was added to PHA-P-stimulated PBMCs of an-
other seronegative Swiss blood donor as recipient cells for the
fresh viral isolate. After a 2-hr incubation with the virus cells
were washed and divided into three cultures of equal size and
treated with the oligodeoxynucleotides and transferred to the
wells of a 48-well plate. One culture received no treatment; the
second culture was treated with TFO A at 1 pM concentration.
After 24 hr supernatant was removed and fresh medium added
containing the ODN at the same concentration (second spike).
The third culture received treatment with TFO SC (random se-
quence control ODN) according to the same treatment sched-
ule. (A) Antiviral effect of TFO A on HIV isolate obtained from
a seropositive asymptomatic individual of category Al of HIV
infection. (B) Antiviral effect of TFO A on HIV isolate ob-
tained from a seropositive symptomatic individual of category
B of HIV infection. (C) Antiviral effect of TFO A on HIV iso-
late obtained from a seropositive symptomatic individual of cat-
egory C3 of HIV infection.
<-
without TFO
TFO SC
TFO A
days post infection
ODN spike
24 hrs post
Infection
ODN spike
2 hrs post
Infection
compared to the untreated culture. Both control cultures ex-
hibited a cytopathic effect.
In a second experiment the inhibition of HIV-1 replication
was tested with a fresh isolate obtained from a symptomatic
seropositive individual of category B of HIV infection, using
the same method of virus isolation and two consecutive treat-
ments with TFO A and TFO SC as described above. Again, the
presence of TFO A resulted in complete inhibition of viral repli-
cation as measured by p24 production (Fig. 3B). No syncytium
formation was detectable in this culture. In the control cultures
treated with the scrambled derivative TFO SC or no
oligodeoxynucleotide, a strong p24 production starts 12 days
postinfection and peaks at day 17 postinfection. Syncytium
formation was observed in the two control cultures beginning
at day 6 postinfection. The maximum levels of p24 produced
with the viral isolate from a symptomatic individual of cate-
gory B of HIV infection, are five times higher than those ob-
tained from an asymptomatic individual of category Al (com-
pare scales of Fig. 3A and B). Such differences in the replica-
tive capacity of two natural viral isolates may occur since these
isolates were obtained from different individuals and different
stages of the disease.
The third blood sample was obtained from a symptomatic
seropositive individual of category C3 of HIV infection. Virus
was isolated and cells were infected with TFO A and TFO SC
as described above. HIV was not able to replicate in the cul-
ture that was treated with TFO A, no viral p24 antigen was de-
tected, and the cells did not exhibit a cytopathic effect (Fig.
3C). In the control cultures p24 antigen expression starts 6 to
9 days postinfection. This viral isolate led to a readily dis-
cernible cytopathic effect.
Synthesis of viral DNA in HTV-infected cells is
prevented by TFO A treatment
To test whether the treatment of HIV-infected PBMCs with
TFO A prevented the synthesis of viral DNA, DNA on in-
fected cells was extracted and subjected to PCR analysis of
day 9 postinfection. To rule out false-negative results with the
clinical isolate due to sequence variation, two pairs of primers
were used, which allowed amplification of the R-U5-region
of the viral LTR and part of the gag gene. The results shown
in Table 1 demonstrate that addition of TFO A prevents syn-
thesis of viral DNA in PBMCs infected with an HIV isolate
of either a symptomatic individual (C3) or the laboratory strain
of HIV-1, while both control cultures allow detection of viral
DNA.
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Table 1. Detection of HIV Viral DNA by Polymerase
Chain Reaction
PCR results 9 days postinfection3
Sample LTR gag
1. PCR experimentb,c
Without TFO 1.475
+TFO SC 1.474
+TFO A 0.017
HIV-negative DNA control 0.017
HIV-positive DNAd control 0.955
2. PCR experimentb,e
Without TFO >2.50
+TFO SC >2.50
+TFO A 0.026
HIV-negative DNA control 0.024
HIV-positive DNAd control 1.419
1.478
1.481
0.012
0.012
1.430
>2.50
2.386
0.017
0.018
2.484
aThe mean values of duplicate experiments are shown.
bCutoff values (mean A450 + 3 SD) for positivity are as follows:
Experiment 1: LTR = 0.022 (n = 16), gag = 0.015 (n = 16)
Experiment 2: LTR = 0.035 (n = 14), gag = 0.024 (n = 14)
The DNA of PBMCs infected with a clinical isolate of an individual
of category C3 of HIV infection (shown in Fig. 3C) and cultured in the
presence or absence of TFOs was subjected to PCR analysis.
dApproximately 5 dsDNA copies of HIV-1. A CEM-derived lympho-
cytic cell line infected with HIV-1 was used.
eThe DNA of C81-66/45 T cells acutely infected with HIV-1 strain(HTLV-IIIB) and cultured in the presence or absence of TFOs was sub-
jected to PCR analysis.
Evaluation of cytotoxicity of triplex-forming
oligonucleotide treatment
To evaluate any cytotoxicity exerted by the ODN treatment,
cell number and viability of the PBMC cells were determined
on day 14 postinfection with the viral isolate of the sympto-
matic individual of category C3 of HIV infection and in two
uninfected PBMC control cultures from the same seronegative
blood donor. The viability of the cells of the culture treated with
TFO A, in which viral replication was inhibited, amounted to
67%. As control for a possible cytotoxic effect of TFO a cul-
ture of uninfected PBMCs was incubated for 6 days in medium
containing 1 pM TFO A. The cells exhibited a viability of 68%,
which is nearly identical to the viability of uninfected cells
grown without TFO A (69%). The viability of the cells with-
out treatment was reduced by the cytopathic effect of the virus
to 28%. In the culture treated with the control TFO SC the cells
exhibited a viability of 31%.
Analysis of the stability of triplex-forming
oligodeoxynucleotides
To evaluate the contribution of the stability of TFOs to the
efficacy of these compounds, TFO A and TFO SC were ra-
dioactively labeled and added to cell cultures (Fig. 4). The
analysis of the remaining full-length ODNs after various times
of incubation demonstrates a rather low stability, which is even
more pronounced for TFO A than for TFO SC. This result in-
dicated that TFO A is a potent inhibitor of viral replication.
DISCUSSION
The PPT was selected as a viral target sequence for anti-
retroviral therapy because it specifies an essential function in
the retroviral life cycle as primer for plus-strand DNA synthe-
sis.14,15 The PPT can be used as target sequence for antisense
100 <>
FIG. 4. Stability of TFO A and TFO SC. C81-66/45 cells
were grown in the presence of radioactively labeled TFO A or
TFO SC in RPMI medium containing 20% fetal bovine serum.
Samples taken at the times indicated were fractionated by elec-
trophoresis on a 12% denaturing polyacrylamide gel. The frac-
tion of undegraded versus total TFO was quantitated by phos-
phorimaging and is indicated by percentage as a function of
time (hours).
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oligodeoxynucleotides.2 The PPT consists of a purine-rich se-
quence. As shown for a site within the 5' end of the human c-
myc gene,16 such sequences are able to serve as target for triple-
helix formation. Here we compared the inhibitory activity of
16-mer ODNs allowing Watson-Crick base pairing in the PPT
region with the antiretroviral activity of TFO A. Only the phos-
phorothioate-modified antisense ODN exhibited a delaying ef-
fect on HIV replication, which, however, appears to be unspe-
cific, since a similar effect was exerted by the randomized
control oligodeoxynucleotide. The result therefore suggests that
short phosphorothioate ODNs may have a sequence-indepen-
dent effect that delays, but does not effectively inhibit, viral
replication. This effect might reflect the results of Ojwang and
co-workers,17 demonstrating that phosphorothioated 18-mer
ODNs exhibited RT inhibition independent of the sequence. We
described earlier that a longer molecule, a 25-mer antisense
ODN, allowing solely Watson-Crick base pairing with the ex-
tended PPT region, could exert a delaying effect on viral repli-
cation lasting from 4 to 6 days.1 However, in contrast to the
experiment described here, the control ODN exhibited no ef-
fect. This result suggests that with antisense ODNs directed
against the PPT the specificity can be raised by increasing the
length of the molecule. In contrast to the rather weak antiviral
effects of 16-mer and 25-mer antisense ODNs, the inhibitory
effect of TFO A was much more pronounced.
We therefore concentrated our efforts on the most effective
inhibitor TFO A. When several different concentrations of TFO
A were tested the concentration for inhibition of HIV ranged
from 1 to 3 pM. We have reported earlier that in vitro a triple
helix as well as an enzyme inhibition were observed if TFO A
was added to an RNase H cleavage reaction at concentrations
higher than 1 pM.1 Inhibition of fresh patient-derived HIV iso-
lates were performed at concentrations of 1 pM. Previously the
T cell line C81-66/45 was used as a target for an acute HIV in-
fection with the laboratory strain HTLV-IIIB and tests for the
efficacy of TFOs. On the basis of this assay, a test was designed
that would allow us to test the inhibitory effect of TFO A in an
acute infection with fresh field isolates of HIV. Virus was iso-
lated from blood samples of three seropositive individuals. The
amounts of viral p24 core antigen released into the culture su-
pernatants, which reflect the amount of virus released, differed
considerably between the cultures of the three isolates. Whether
this is due to the wide spectrum of biological variability in vi-
ral replication rates that have been described in primary HIV
isolates,18,19 is not clear. Data on the high dynamics of HIV
replication in vivo20 indicate that variations of replication rates
observed in vitro may reflect not only the replicative capacity
of a viral isolate but also differences of the target cell popula-
tions used for isolation in vitro.21 Peak levels of retroviral p24
antigen found in supernatants between 9 and 15 days postin-
fection ranged from 0.2 ng/ml in an untreated culture from a
patient of category C3 up to 4.2 ng/ml in an untreated culture
from another patient of category B.
Oligodeoxynucleotides, especially if thioated, can interfere
with virus uptake, as has been described.22 Oligode-
oxynucleotides were therefore added to the cells 2 hr after the
virus to avoid interference with binding of HIV to the CD4 re-
ceptor molecule. A control culture was kept without TFO to
prove that under the conditions used, the amount of virus was
sufficient to establish an infection. TFO SC, having the same
base composition and identical modifications, showed no in-
hibitory effect on viral replication. Since TFO A is able to sup-
press viral replication during the whole culture period without
further addition of the ODN, it can be concluded that the TFO
A has an intracellular effect, e.g., by prevention of the estab-
lishment of infection. A third TFO molecule, consisting of a
54-nucleotide sequence and termed TFO B, was used as an ad-
ditional specificity control. This molecule contains a GT-alter-
nating sequence in its Hoogsteen base-pairing part while its
Watson-Crick base-pairing part is unchanged. Thus TFO B can-
not form a triple helix. TFO B exhibited no antiretroviral ef-
fect in cell culture (data not shown). Thus we conclude that the
effect of TFO A in cell culture is caused specifically by the
structure of this compound.
TFO A can combine with the viral target RNA to form a
triple helix as shown in Fig. 5A and described previously by
melting studies in vitro. ' With the two exceptions, the TTA and
TCG triplets in positions 17 and 18 of the extended PPT, the
triple helix could be rather stable. Theoretically it could form
with the incoming viral RNA as well as with progeny RNA.
However, the strength of the effect in cell culture and the lack
of viral breakthrough during extended culturing suggest that no
DNA provirus is formed either by triplex formation on the in-
coming viral RNA or by direct inhibition of the RT. On the ba-
sis of the nucleotide sequence the TFO A can form a hairpin-like
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FIG. 5. Predicted secondary structures: (A) TFO A alignment
on the target RNA sequence; =, Hoogsteen base pairing; -,
Watson-Crick base pairing. Modified nucleotides are marked
by asterisks. (B) Folding of TFO A was done by the StemLoop
program of the Wisconsin Sequence Analysis Package. (C)
Scrambled TFO sequence listed for comparison.
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stem-loop structure shown in Fig. 5B. This structure of the TFO
A resembles the DNA inhibitor molecules of the reverse tran-
scriptase of HIV-1 described by Schneider and co-workers.23
Some of these molecules evolved by the systematic evolution of
ligands by exponential enrichment (SELEX) method possess dif-
ferent conserved helices interrupted by loops, bulges, or mis-
matched base pairs. These structural features are shared by TFO
A. In vitro an inhibitory effect on the RT as well as on the RNase
H has been shown to occur in the absence of a specific target
RNA strand of TFO A.1 Altogether the inhibitory effect of TFO
A in cell culture may therefore be due to a superposition of a
triple-helix effect and a direct enzyme inhibition. These dual in-
hibitory functions should be less likely to induce resistance, since
two target sites are affected simultaneously.
Finally, it has been found that biologic effects, thought to be
caused by the specific interaction of ODNs with their nucleic
acid target, could be due to the presence of G tetrads and phos-
phorothioate modifications.24 In our case this seems less likely,
since TFO SC also contains five contiguous G residues and
bears phosphorothioate modifications at the same positions as
TFO A, while not being able to inhibit HIV infection. Apart
from the potential use of the here-described compound for in-
hibition of HIV replication, it may contribute to a more funda-
mental understanding of nucleic acid-based therapies.
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